ERBB2 and breast cancer: To this end, two ongoing phase II studies in China are evaluating FCN-437c alone versus in combination with letrozole (NCT04488107) [40], or in combination with fulvestrant or letrozole plus goserelin (NCT05004142) [41] in patients with HR+/HER2– advanced breast cancer; in addition, two ongoing phase III trials are evaluating FCN-437c versus placebo in combination with letrozole or anastrozole with or without goserelin (NCT05439499) or FCN-437c versus placebo in combination with fulvestrant with or without goserelin (NCT05438810) in patients with HR+/HER2– advanced breast cancer.